Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 2:2022:6265198.
doi: 10.1155/2022/6265198. eCollection 2022.

Acacetin as a Potential Protective Compound against Cardiovascular Diseases

Chunxuan Wu  1 , Jianhua Yan  1 , Wei Li  1
Affiliations
Review

Acacetin as a Potential Protective Compound against Cardiovascular Diseases

Chunxuan Wu et al. Evid Based Complement Alternat Med. .

Abstract

Acacetin (5,7-dihydroxy-4'-methoxyflavone) is the major bioactive component of the traditional Chinese medicine "Snow lotus". As a natural flavonoid compound, it has been shown to have good pharmacological effects such as anti-inflammatory, anticancer, and anti-obesity. Among them, its prominent role in cardiovascular diseases (CVD) has received extensive attention from scholars in recent years. In this review, the protective effects of acacetin on a variety of cardiovascular diseases, as well as the existing problems and prospects, are discussed and summarized. This review also highlights the great potential of acacetin, a natural-derived Chinese medicine, as a cardiovascular agent candidate.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have any conflicts of interest.

Figures

Figure 1
Figure 1
Chemical structure of acacetin.
Figure 2
Figure 2
Pharmacological properties of acacetin in cardiovascular diseases.
See this image and copyright information in PMC

References

    1. Timmis A., Townsend N., Gale C., et al. European society of cardiology: cardiovascular disease statistics 2017. European Heart Journal . 2018;39:508–579. doi: 10.1093/eurheartj/ehx628. - DOI - PubMed
    1. Benjamin E. J., Virani S. S., Callaway C. W., et al. Heart disease and stroke statistics-2018 update: a report from the American heart association. Circulation . 2018;137:e67–e492. doi: 10.1161/CIR.0000000000000558. - DOI - PubMed
    1. Roth G. A., Forouzanfar M. H., Moran A. E., et al. Demographic and epidemiologic drivers of global cardiovascular mortality. New England Journal of Medicine . 2015;372(14):1333–1341. doi: 10.1056/NEJMoa1406656. - DOI - PMC - PubMed
    1. Tachjian A., Maria V., Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases. Journal of the American College of Cardiology . 2010;55(6):515–525. doi: 10.1016/j.jacc.2009.07.074. - DOI - PMC - PubMed
    1. Feng X., Sureda A., Jafari S., et al. Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. Theranostics . 2019;9(7):1923–1951. doi: 10.7150/thno.30787. - DOI - PMC - PubMed